Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Invisible Condom is a topical microbicide vaginal gel developed by researchers at the Infectious Diseases Research Centre of Laval University for the prevention of HIV and other sexually transmitted infections (STIs). The formulation consists of 2% sodium lauryl sulfate (SLS), a surfactant, incorporated into a thermoreversible gel base composed of a 30% polyoxyethylene-polyoxypropylene block copolymer in a pH 4.0 citrate buffer. The product exerts its protective effect through a dual mechanism: the gel provides a physical barrier that prevents pathogens from reaching the vaginal and cervical mucosa, while the SLS acts as a chemical barrier by disrupting the lipid membranes of viruses and bacteria. It is designed to target a broad spectrum of pathogens, including HIV-1, herpes simplex virus type 2 (HSV-2), human papillomavirus (HPV), Neisseria gonorrhoeae, and Chlamydia trachomatis. The gel is administered via a proprietary vaginal applicator designed for uniform distribution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Invisible Condom.